公开(公告)号：US11419871B2

公开(公告)日：2022-08-23

申请号：US17014011

申请日：2020-09-08

Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH

Inventor： Ryohei Katayama ,  Ken Uchibori ,  Naoya Fujita

IPC: A61K31/506 ,  A61K31/662 ,  G01N33/574 ,  C12Q1/68 ,  A61P35/00 ,  A61K45/06

Abstract: A drug containing, as an active ingredient, a compound represented by ALK inhibitors such as brigatinib, AP26113-analog, and AZD3463 has been found to be effective against a non-small cell lung cancer having a point mutation at C797S in EGFR which has acquired a resistance to chemotherapy agents. Further, the drug used in combination with an anti-EGFR antibody demonstrates a notable suppression effect on the tumor growth. The drug has a potential to be a therapeutic agent effective against a non-small cell lung cancer which is resistant to gefitinib, a first generation therapeutic agent and osimertinib, a third generation therapeutic agent.

公开(公告)号：US20250099461A1

公开(公告)日：2025-03-27

申请号：US18263947

申请日：2022-02-10

Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH

Inventor： Ryohei Katayama

IPC: A61K31/497 ,  C12Q1/6886

Abstract: Tumors having acquired resistance to ALK-TKIs were analyzed by use of various kinase inhibitors. As a result, it was found that gilteritinib, which is a therapeutic drug for FLT3 gene mutation-positive acute myeloid leukemia, has an effect on the tumors. Gilteritinib directly inhibits the kinase activity of ALK to have an effect on an ALK fusion gene mutation-positive tumor having a plurality of compound mutations for which effective therapeutic drugs have been not present. ALK-TKI-resistant cancer developed via a fusion gene such as NTRK, ROS1 and LTK, and via AXL can be effectively overcome by gilteritinib alone, and the resistance mediated through ALK-TKI resistance mechanism via a bypass pathway such as KRAS, BRAF and EGFR, can be overcome by combination therapy.

公开(公告)号：US10921311B2

公开(公告)日：2021-02-16

申请号：US16070110

申请日：2017-01-13

Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH

Inventor： Kengo Takeuchi ,  Seiji Sakata ,  Yuki Togashi ,  Naoya Fujita ,  Ryohei Katayama

IPC: C07H21/04 ,  C12Q1/68 ,  G01N33/50 ,  C12N9/12 ,  G01N33/574 ,  C12N9/88 ,  C07K14/82 ,  A61K31/519 ,  A61P35/00 ,  A61K38/00 ,  C12N15/113 ,  C12N15/62 ,  C12Q1/6886 ,  C12Q1/6853 ,  C12Q1/686

Abstract: It is intended to reveal a polynucleotide serving as a novel causative gene of a cancer and, on the basis of this finding, to provide a method for detecting the polynucleotide or a polypeptide encoded thereby, a kit and a primer set for the detection, a method for screening for a substance that inhibits the polypeptide, and a pharmaceutical composition for the treatment of a cancer, containing the inhibiting substance. The detection method of the present invention detects a BRAF fusion protein or a fusion gene encoding the fusion protein, or a PXN or GMDS fusion protein or a fusion gene encoding the fusion protein in a digestive organ-derived sample obtained from a subject.

公开(公告)号：US20230323475A1

公开(公告)日：2023-10-12

申请号：US18314267

申请日：2023-05-09

Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH

Inventor： Kengo Takeuchi ,  Kana Sakamoto ,  Ryohei Katayama ,  Seiji Sakata

IPC: C12Q1/6886 ,  A61K31/167 ,  G01N33/50 ,  G01N33/48 ,  A61K31/551 ,  G01N33/574 ,  A61K31/4745 ,  A61K45/00 ,  C12Q1/68 ,  A61P35/02 ,  A61P43/00 ,  A61K31/4045 ,  A61K31/55 ,  A61K31/635 ,  A61K31/675

CPC classification number: C12Q1/6886 ,  A61K31/167 ,  G01N33/5023 ,  G01N33/48 ,  G01N33/5011 ,  G01N33/5047 ,  A61K31/551 ,  G01N33/57426 ,  A61K31/4745 ,  A61K45/00 ,  G01N33/5748 ,  C12Q1/68 ,  A61P35/02 ,  A61P43/00 ,  A61K31/4045 ,  A61K31/55 ,  A61K31/635 ,  A61K31/675 ,  G01N2333/82 ,  C12Q2600/158 ,  G01N2800/56 ,  C12Q2600/16

Abstract: The diagnostic markers that provide novel diagnostic criteria to blastic plasmacytoid dendritic cell neoplasm (BPDCN) has been searched, and the presence of immunoblastoid cytomorphology, 8q24 rearrangement, and MYC expression were established as novel markers for subtyping BPDCN. It has been further found that the inhibitors which directly or indirectly inhibit the expression, functions, or signaling pathways of MYC, such as BET bromodomain-selective inhibitors or aurora kinase inhibitors, are effective in MYC-positive BPDCN, and HDAC inhibitors or BCL2 family protein inhibitors are effective as therapeutic drugs for BPDCN.

公开(公告)号：US10813933B2

公开(公告)日：2020-10-27

申请号：US16302207

申请日：2017-05-17

Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH

Inventor： Ryohei Katayama ,  Ken Uchibori ,  Naoya Fujita

IPC: A61K31/506 ,  A61K31/662 ,  G01N33/574 ,  C12Q1/68 ,  A61P35/00 ,  A61K45/06

Abstract: A drug containing, as an active ingredient, a compound represented by ALK inhibitors such as brigatinib, AP26113-analog, and AZD3463 has been found to be effective against a non-small cell lung cancer having a point mutation at C797S in EGFR which has acquired a resistance to chemotherapy agents. Further, the drug used in combination with an anti-EGFR antibody demonstrates a notable suppression effect on the tumor growth. The drug has a potential to be a therapeutic agent effective against a non-small cell lung cancer which is resistant to gefitinib, a first generation therapeutic agent and osimertinib, a third generation therapeutic agent.

公开(公告)号：US20190033293A1

公开(公告)日：2019-01-31

申请号：US16070110

申请日：2017-01-13

Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH

Inventor： Kengo Takeuchi ,  Seiji Sakata ,  Yuki Togashi ,  Naoya Fujita ,  Ryohei Katayama

IPC: G01N33/50 ,  A61K38/00 ,  C12N15/62 ,  C12N9/12 ,  C12N9/88 ,  C12N15/113 ,  A61P35/00

Abstract: It is intended to reveal a polynucleotide serving as a novel causative gene of a cancer and, on the basis of this finding, to provide a method for detecting the polynucleotide or a polypeptide encoded thereby, a kit and a primer set for the detection, a method for screening for a substance that inhibits the polypeptide, and a pharmaceutical composition for the treatment of a cancer, containing the inhibiting substance. The detection method of the present invention detects a BRAF fusion protein or a fusion gene encoding the fusion protein, or a PXN or GMDS fusion protein or a fusion gene encoding the fusion protein in a digestive organ-derived sample obtained from a subject.

公开(公告)号：US20240285587A1

公开(公告)日：2024-08-29

申请号：US18572244

申请日：2022-06-24

Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH

Inventor： Satoshi Takagi ,  Ryohei Katayama

IPC: A61K31/4192 ,  A61K31/192 ,  A61K31/195 ,  A61K31/40 ,  A61K31/42 ,  A61P35/00 ,  G01N33/50

CPC classification number: A61K31/4192 ,  A61K31/192 ,  A61K31/195 ,  A61K31/40 ,  A61K31/42 ,  A61P35/00 ,  G01N33/5023 ,  G01N2333/726

Abstract: It has been revealed that lysophosphatidic acid (LPA) functions as a mediator that augments invasive ability in osteosarcoma. Furthermore, it has been found that LPAR1, which is a receptor for LPA, is highly expressed in osteosarcoma and glioma, and the LPA-LPAR1 interaction is involved in the metastasis and proliferation of osteosarcoma and glioma. Examinations carried out on the basis of these findings have found that LPAR1 antagonists can serve as therapeutic agents for suppressing the metastasis and proliferation of osteosarcoma and glioma.

公开(公告)号：US12055538B2

公开(公告)日：2024-08-06

申请号：US17144776

申请日：2021-01-08

Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH

Inventor： Kengo Takeuchi ,  Seiji Sakata ,  Yuki Togashi ,  Naoya Fujita ,  Ryohei Katayama

IPC: C07H21/04 ,  A61K31/519 ,  A61K38/00 ,  A61P35/00 ,  C07K14/82 ,  C12N9/12 ,  C12N9/88 ,  C12N15/113 ,  C12N15/62 ,  G01N33/50 ,  G01N33/574 ,  C12Q1/6853 ,  C12Q1/686 ,  C12Q1/6886

CPC classification number: G01N33/5011 ,  A61K31/519 ,  A61K38/005 ,  A61P35/00 ,  C07K14/82 ,  C12N9/12 ,  C12N9/88 ,  C12N15/113 ,  C12N15/62 ,  C12Y207/11025 ,  C12Y402/01047 ,  G01N33/57446 ,  C12Q1/6853 ,  C12Q1/686 ,  C12Q1/6886

Abstract: It is intended to reveal a polynucleotide serving as a novel causative gene of a cancer and, on the basis of this finding, to provide a method for detecting the polynucleotide or a polypeptide encoded thereby, a kit and a primer set for the detection, a method for screening for a substance that inhibits the polypeptide, and a pharmaceutical composition for the treatment of a cancer, containing the inhibiting substance. The detection method of the present invention detects a BRAF fusion protein or a fusion gene encoding the fusion protein, or a PXN or GMDS fusion protein or a fusion gene encoding the fusion protein in a digestive organ-derived sample obtained from a subject.

公开(公告)号：US11781115B2

公开(公告)日：2023-10-10

申请号：US16782579

申请日：2020-02-05

Applicant: TOPPAN PRINTING CO., LTD. ,  Japanese Foundation For Cancer Research

Inventor： Yuki Takahashi ,  Shiro Kitano ,  Ryohei Katayama ,  Satoshi Nagayama

IPC: C12N5/09

CPC classification number: C12N5/0693 ,  C12N2502/11 ,  C12N2502/1323 ,  C12N2502/28 ,  C12N2509/10 ,  C12N2513/00 ,  C12N2533/30 ,  C12N2533/90

Abstract: A primary culture method in which cells contained in a tissue collected from a living body are primary cultured in vitro, in which the cells in the tissue collected from the living body are seeded and cultured on a top surface of a cell structure containing cells constituting a stroma and composed of a single layer or two or more cell layers laminated in the thickness direction.

公开(公告)号：US20210140943A1

公开(公告)日：2021-05-13

申请号：US17144776

申请日：2021-01-08

Applicant: JAPANESE FOUNDATION FOR CANCER RESEARCH

Inventor： Kengo Takeuchi ,  Seiji Sakata ,  Yuki Togashi ,  Naoya Fujita ,  Ryohei Katayama

IPC: G01N33/50 ,  C12N9/12 ,  G01N33/574 ,  C12N9/88 ,  C07K14/82 ,  A61K31/519 ,  A61P35/00 ,  A61K38/00 ,  C12N15/113 ,  C12N15/62

Abstract: It is intended to reveal a polynucleotide serving as a novel causative gene of a cancer and, on the basis of this finding, to provide a method for detecting the polynucleotide or a polypeptide encoded thereby, a kit and a primer set for the detection, a method for screening for a substance that inhibits the polypeptide, and a pharmaceutical composition for the treatment of a cancer, containing the inhibiting substance. The detection method of the present invention detects a BRAF fusion protein or a fusion gene encoding the fusion protein, or a PXN or GMDS fusion protein or a fusion gene encoding the fusion protein in a digestive organ-derived sample obtained from a subject.